ME02628B - Modulatori farmakokinetičkih svojstava lekova - Google Patents

Modulatori farmakokinetičkih svojstava lekova

Info

Publication number
ME02628B
ME02628B MEP-2016-260A MEP26016A ME02628B ME 02628 B ME02628 B ME 02628B ME P26016 A MEP26016 A ME P26016A ME 02628 B ME02628 B ME 02628B
Authority
ME
Montenegro
Prior art keywords
therapeutics
modulators
pharmacokinetic properties
pharmacokinetic
properties
Prior art date
Application number
MEP-2016-260A
Other languages
German (de)
English (en)
French (fr)
Inventor
Manoj C Desai
Allen Y Hong
Hon C Hui
Hongtao Liu
Radall W Vivian
Lianhong Xu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46465350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02628(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority claimed from EP12167589.6A external-priority patent/EP2487161B2/en
Publication of ME02628B publication Critical patent/ME02628B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MEP-2016-260A 2007-02-23 2008-02-22 Modulatori farmakokinetičkih svojstava lekova ME02628B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90322807P 2007-02-23 2007-02-23
US95871607P 2007-07-06 2007-07-06
EP12167589.6A EP2487161B2 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics

Publications (1)

Publication Number Publication Date
ME02628B true ME02628B (me) 2017-06-20

Family

ID=46465350

Family Applications (4)

Application Number Title Priority Date Filing Date
MEP-2016-241A ME02582B (me) 2007-02-23 2008-02-22 Modulatori farmakokinetičkih svojstava terapeutika
MEP-2016-263A ME02631B (me) 2007-02-23 2008-02-22 Modulatori farmakokinetičkih svojstava lijekova
MEP-2016-262A ME02680B (me) 2007-02-23 2008-02-22 Modulatori farmakokinetickih svojstava lijekova
MEP-2016-260A ME02628B (me) 2007-02-23 2008-02-22 Modulatori farmakokinetičkih svojstava lekova

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MEP-2016-241A ME02582B (me) 2007-02-23 2008-02-22 Modulatori farmakokinetičkih svojstava terapeutika
MEP-2016-263A ME02631B (me) 2007-02-23 2008-02-22 Modulatori farmakokinetičkih svojstava lijekova
MEP-2016-262A ME02680B (me) 2007-02-23 2008-02-22 Modulatori farmakokinetickih svojstava lijekova

Country Status (8)

Country Link
EP (6) EP2487167A1 (me)
DK (3) DK2487161T4 (me)
HU (2) HUS1600053I1 (me)
ME (4) ME02582B (me)
PL (2) PL2487166T3 (me)
RS (4) RS55459B1 (me)
SI (4) SI2487166T1 (me)
UA (1) UA101312C2 (me)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150004239A1 (en) * 2012-01-12 2015-01-01 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
EP1733725B2 (en) 1999-06-04 2012-08-08 Abbott Laboratories Pharmaceutical solution comprising ritonavir, a solvent (long chain fatty acid) and water
EP3696171A1 (en) 2006-07-07 2020-08-19 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ES2603617T3 (es) 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de la terapéutica

Also Published As

Publication number Publication date
HUS1600053I1 (hu) 2017-01-30
HUS1600052I1 (hu) 2017-01-30
EP2487168A1 (en) 2012-08-15
RS55459B1 (sr) 2017-04-28
EP2487166B1 (en) 2016-07-27
PL2487163T3 (pl) 2017-04-28
EP2487166A1 (en) 2012-08-15
SI2487162T1 (sl) 2016-12-30
SI2487166T1 (sl) 2017-02-28
DK2487161T3 (en) 2016-10-24
EP2487162B1 (en) 2016-08-17
EP2487164A1 (en) 2012-08-15
EP2487163A1 (en) 2012-08-15
SI2487163T1 (sl) 2016-12-30
DK2487163T3 (en) 2016-10-24
RS55280B1 (sr) 2017-03-31
UA101312C2 (ru) 2013-03-25
DK2487161T4 (da) 2024-06-24
ME02631B (me) 2017-06-20
DK2487162T3 (en) 2016-10-24
RS55351B1 (sr) 2017-03-31
EP2487167A1 (en) 2012-08-15
SI2487161T1 (sl) 2016-12-30
EP2487163B1 (en) 2016-08-17
RS55195B1 (sr) 2017-01-31
ME02680B (me) 2017-06-20
ME02582B (me) 2017-06-20
EP2487162A1 (en) 2012-08-15
PL2487166T3 (pl) 2017-07-31

Similar Documents

Publication Publication Date Title
HUS2000013I1 (hu) Gyógyszerek farmakokinetikai tulajdonságainak modulátorai
HRP20150744T1 (en) Modulators of pharmacokinetic properties of therapeutics
HK1143144A1 (en) Modulators of pharmacokinetic properties of therapeutics
HUS1600052I1 (hu) Terápiás szerek farmakokinetikai paramétereinek modulálása